Atrial fibrillation, valvular heart disease, and use of target-specific oral anticoagulants for stroke prevention

被引：7
|
作者：
Hohnloser, Stefan H.
Lopes, Renato D.
机构：
[1] Goethe Univ Frankfurt, Dept Cardiol, D-60590 Frankfurt, Germany
[2] Duke Med, Duke Clin Res Inst, Durham, NC USA
来源：
EUROPEAN HEART JOURNAL | 2014年 / 35卷 / 47期
关键词：
WARFARIN; DABIGATRAN; APIXABAN;
D O I：
10.1093/eurheartj/ehu386
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
This editorial refers to 'Clinical characteristics and outcomes with rivaroxaban vs. warfarin in patients with non-valvular atrial fibrillation but underlying native mitral and aortic valve disease participating in the ROCKET AF trial'(+), by G. Breithardt et al. on page 3377.
引用
收藏
页码：3323 / 3325
页数：3
相关论文
共 50 条
  • [21] Can Direct Oral Anticoagulants Be Used for Stroke Prevention Among Patients with Valvular Atrial Fibrillation?
    Anderson, Sarah L.
    Marrs, Joel C.
    [J]. CURRENT CARDIOLOGY REPORTS, 2019, 21 (10)
  • [22] Novel oral anticoagulants for stroke prevention in atrial fibrillation
    Taylor, Jennifer
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (12) : 1419 - 1420
  • [23] New Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation
    Hilleman, Daniel E.
    [J]. AMERICAN JOURNAL OF PHARMACY BENEFITS, 2012, 4 (06) : 269 - 283
  • [24] The effectiveness of oral anticoagulants in the prevention of stroke in patients with non-valvular atrial fibrillation: results from the Stroke Prevention and Anticoagulants (SPA) study
    Grimaldi-Bensouda, L.
    Le Heuzey, J. Y.
    Ferrieres, J.
    Leys, D.
    Davy, J. M.
    Martinez, M.
    Smadja, D.
    Ellie, E.
    Sablot, D.
    Nighoghossian, N.
    Benichou, J.
    Touze, E.
    Abenhaim, L.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 29 - 29
  • [25] Direct-acting oral anticoagulants in patients with atrial fibrillation and valvular heart disease
    Canales, Natalie
    Cao, Tina
    Fakourfar, Neeloufar
    Snee, Mara
    Tsu, Laura
    [J]. JAAPA-JOURNAL OF THE AMERICAN ACADEMY OF PHYSICIAN ASSISTANTS, 2022, 35 (09): : 17 - 18
  • [26] SAFETY AND EFFICACY OF DIRECT ORAL ANTICOAGULANTS IN PATIENTS WITH ATRIAL FIBRILLATION AND VALVULAR HEART DISEASE
    Lippmann, Matthew
    Apte, Nachiket
    Pierpoline, Michael
    Taduru, Siva Sagar
    Dehkordi, Seyed Hamed Hosseini
    Isom, Nicholas
    Dalia, Tarun
    Hacker, Ethan
    Robinson, Alexander
    Buechler, Tyler
    Jazayeri, Mohammad-Ali
    Masoomi, Reza
    Sheldon, Seth
    Reddy, Madhu
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2019, 73 (09) : 501 - 501
  • [27] Reversal of target-specific oral anticoagulants
    Scott Kaatz
    Mark Crowther
    [J]. Journal of Thrombosis and Thrombolysis, 2013, 36 : 195 - 202
  • [28] Monitoring target-specific oral anticoagulants
    Konkle, Barbara A.
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2014, : 329 - 333
  • [29] Stability of renal function in patients with atrial fibrillation switched from warfarin to target-specific oral anticoagulants
    Minhas, A.
    Jiang, Q.
    Gu, X.
    Haymart, K.
    Kline-Rogers, E.
    Almany, S.
    Kozlowski, J.
    Krol, G. D.
    Kaatz, S.
    Froehlich, J. B.
    Barnes, G. D.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 904 - 904
  • [30] Reversal of target-specific oral anticoagulants
    Siegal, Deborah M.
    Cuker, Adam
    [J]. DRUG DISCOVERY TODAY, 2014, 19 (09) : 1465 - 1470
12345